Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial
This RCT (n=985) found ursodeoxycholic acid prophylaxis did not significantly reduce the occurrence of symptomatic gallstone disease vs placebo (6.5% vs 9.7%, RR 0·67, 95% CI 0.43–1.04, p=0.071) but did reduce occurrence in patients without gallstones before surgery (p=0.0016).
Source:
Lancet Gastroenterology and Hepatology
SPS commentary:
Commentary is provided on the prevalence of obesity and gallstones and the increased chances of gallstone formation after bariatric surgery which has been increasing as the number of patients undergoing the surgery has increased.